The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr class="thead"><td class="align_left">Strategy</td><td class="align_center">Cost (US$)</td><td class="align_center">Effectiveness (QALYs)</td><td class="align_center">Increase cost (US$)</td><td class="align_center">Increase QALY (QALYs)</td><td class="align_center">ICER (US$/QALYs)</td></tr><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr><td class="align_left">TIO</td><td class="align_center">5836.49</td><td class="align_center">1.543</td><td class="align_center">—</td><td class="align_center">—</td><td class="align_center">—</td></tr><tr><td class="align_left">UMEC/VI</td><td class="align_center">5070.82</td><td class="align_center">1.545</td><td class="align_center">−765.67</td><td class="align_center">0.002</td><td class="align_center">Dominant</td></tr><tr class="table-tr"><td colspan="6"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Costs and effectiveness of UMEC/VI versus TIO in the base case analysis over a three-year period.</div>

Canadian Respiratory Journal

tab5

Table 5

Table 5: The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease 

Table 5 | The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease 